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INTRODUCTION
The main purpose of this work is to identify new prophylaxes and therapeutics for the transmissible spongiform encephalopathies (TSEs) or prion diseases. Although some effective experimental post-exposure prophylactic treatments have been identified that can substantially increase the survival times of prion-infected animals if treatments are initiated well in advance of the onset of clinical signs of disease [reviewed in (1) ], no treatments that are known to be effective once clinical signs have appeared. To aid in the search for anti-TSE compounds, we have continued to develop new in vitro screens for inhibitors of pathological prion protein accumulation and to test new ways of administering such compounds to infected animals to improve their survival times.
BODY

Introduction
The transmissible spongiform encephalopathies (TSEs) or prion diseases are infectious neurodegenerative syndromes of mammals that include bovine spongiform encephalopathy (BSE), chronic wasting disease (CWD) of deer and elk, scrapie in sheep, and Creutzfeld-Jakob disease (CJD) in humans. TSEs have incubation periods of months to years but after the appearance of clinical signs are rapidly progressive, untreatable, and invariably fatal. Attempts to develop therapeutic strategies for these diseases are hobbled by gaping holes in the understanding of the transmissible agent (or prion) and the pathologic consequences of its propagation in the host. Nonetheless, recent studies have placed tighter limits on the nature of TSE infectivity, suggested salient features of TSE neurotoxicity, and revealed new anti-TSE compounds and treatment regimens that prolong the lives of infected individuals.
The Nature of TSE Infectivity: Protein-Only Prions?
The full molecular nature of TSE infectivity and its propagation mechanism remain unclear. One critical component appears to be an abnormal form of prion protein called PrP Sc . PrP Sc is defined loosely by its apparent association with TSE infectivity but, otherwise, has variable properties and is poorly understood structurally. 1 Usually, if not always, PrP Sc is multimeric and has greater sheet secondary structure and protease resistance than normal PrP (PrP C ). Relative protease resistance is often used practically to discriminate PrP Sc from PrP C and gives rise to the operationally defined alternative term, PrP-res. PrP Sc is made post-translationally from the normal proteasesensitive prion protein. The mechanism of this conversion is not well understood but involves the ability of multimeric PrP Sc to bind PrP C and induce a conformational change as PrP C is recruited into the growing PrP Sc multimer.
The prion hypothesis posits that PrP
Sc is the only necessary component of TSE infectivity. 2 Efforts to test this hypothesis have led to recent reports of the in vitro generation of TSE prions. 3, 4 Synthetic truncated prion protein (PrP) fibril preparations were shown to accelerate disease when inoculated into transgenic mice that vastly overexpress the same truncated PrP construct. 4 However, these fibrils were not infectious for normal mice and thus were g10 8 -fold less infectious than bona fide PrP Sc .
Although it was concluded that prions had been synthesized from recombinant PrP C alone, the lack of controls leaves open the possibility that the recipient transgenic mice were spontaneously making prions.
In contrast, others have shown compelling evidence for continuous serial amplification of robust TSE infectivity in cell-free reactions containing crude brain homogenate. 3 This landmark result virtually eliminates the possibility that replication of an agent-specific nucleic acid genome is required. However, these studies also do not prove the "prion protein-only" model for TSE infectivity because many other host-encoded molecules besides PrP were present in the reaction.
The Most Infectious Prion Protein Particles
A fundamental question with many neurodegenerative protein misfolding diseases is whether large fibrillar deposits or smaller subfibrillar oligomers are the prime causes of disease. 1 To address this question with respect to TSE diseases and characterize the basic infectious unit of TSE infectivity, we have fractionated infectious PrPcontaining aggregates by flow field-flow fractionation and compared their infectivity per unit protein (i.e., specific infectivity). 5 Nonfibrillar particles between about 300-600 kDa (mass equivalent to ∼14-28 PrP molecules) had much higher specific infectivity than larger fibrils or smaller oligomers (e5-mers) of PrP. These most infectious particles were ∼25 nm in diameter, consistent with particles detected previously in filtration 6 and field flow fractionation 7 experiments. In our analyses, the infectivity levels were nearly proportional to the concentration of particles rather than protein, suggesting that as long as PrP Sc oligomers are above a minimal size, they are similarly infectious in vivo. 5 Accordingly, per unit mass, smaller particles are more infectious than larger ones. Although the predominant protein constituent of the "most infectious" particles was PrP, it remains possible that other molecular constituents are important.
Thus, our results also fall short of providing firm support for a protein-only nature of mammalian prions. On the contrary, it seems just as plausible to argue that host-derived molecules besides PrP might be required for robust TSE infectivity. For example, there is growing evidence that sulfated glycosaminoglycans (GAGs), [8] [9] [10] nucleic acids, or both could be essential, at least as cofactors in pathological PrP conversion. [11] [12] [13] Indeed, as discussed below, compounds such as these, or analogues thereof, can interact with PrP, alter its conformation, and have potent anti-TSE activities. Nonetheless, these findings support the emerging view that with many protein aggregation diseases, smaller nonfibrillar oligomers are more pathological than large fibrils or clusters of fibrils (plaques).
Neuropathologic Mechanisms
Although the enigmatic PrP Sc multimer seems almost certain to be a major component of the transmissible agent, it is not necessarily the main neurotoxin of TSE diseases. Alternative forms of PrP have also been observed that may play primary roles in neuropathogenesis (reviewed in ref 1). Furthermore, there is evidence that the neuropathology of TSE infections is greatly enhanced by the presence of PrP C 14,15 and, more specifically, PrP C that is anchored to cellular membranes by its glycophosphatidylinositol (GPI) anchor. 16 In scrapie-infected transgenic mice expressing only anchorless PrP C , PrP Sc (PrP-res) and TSE infectivity are propagated, but the resulting neuropathological and clinical effects are dramatically reduced. 16 Thus, it is likely that in addition to being the substrate for PrP Sc formation, GPI-anchored PrP C somehow transduces or potentiates the neurotoxicity of TSE infections.
Prophylactic and Therapeutic Strategies
Despite fundamental uncertainties regarding the infectious agent, its replication mechanism, and neuropathological manifestations, a number of anti-TSE interventions have been pursued. An important but elusive goal is to be able to treat the disease after the appearance of clinical signs. This will most likely involve some combination of inhibiting PrP Sc formation, destabilizing existing PrP Sc , blocking neurotoxic effects of the infection, and promoting the recovery of lost functions in the central nervous system (CNS). Another worthwhile goal is to reduce the risk of infection in the first place by neutralizing sources of infection, blocking infections via the most common peripheral routes, or blocking neuroinvasion from the periphery. Although immunotherapies are being pursued with some tantalizing results, 17, 18 we have focused primarily on chemotherapeutic approaches. Although no clinically proven anti-TSE drug has been developed, significant progress has been made, especially in identifying compounds with prophylactic activity.
In Vitro Screens for Anti-PrP Sc Compounds
Most TSE drug discovery efforts to date have attacked PrP Sc accumulation. 17 Our usual approach has been first to screen for inhibitors using TSE-infected cell cultures and then to test the most promising inhibitors against scrapie infections in rodents. Higher throughput screens have enabled the testing of thousands of compounds against multiple strains of murine and sheep scrapie in cell cultures. 19, 20 Recent development of the first deer cell line chronically infected with CWD has enabled us to begin screening compounds for activity against this cervid TSE disease as well. 21 Unfortunately, no cell lines are available that are infected with BSE or human CJD, despite the great significance of these TSEs to public health and agriculture. The importance of testing compounds against multiple TSEs in multiple cell types is indicated by the striking species and strain specificities of PrP Sc inhibitors that have been observed already. 19, 20 
Testing in Animals
A much slower process in TSE drug development is the testing of compounds against infections in animals. Despite possible problems with strain and species dependence of anti-TSE compounds, most in vivo testing has been done in rodents, which allow for much faster and less expensive screening than is possible in the natural, large-animal host species. Drug treatments initiated after high-dose intracerebral inoculations test for potential therapeutic activities in hosts with established CNS infections, the most difficult challenge in TSE therapeutics. Often it is also of interest to test for prophylactic protection against lower dose inoculations by peripheral routes (e.g., intraperitoneal).
Anti-TSE Compounds
A growing list of compounds has been reported to have anti-TSE activity in vitro and in vivo ( 22 certain cyclic tetrapyrroles (cTPs), [23] [24] [25] and phosphorothioated oligonucleotides (PS-ONs) 26, 27 can more than triple survival times of rodents inoculated intraperitoneally with high scrapie titers (e.g., 10 3 -10 4 lethal doses) and completely protect animals receiving lower titers. In contrast, few compounds are known to have any beneficial effects if treatment is initiated after infection of the CNS. Many of the test compounds that are effective prophylactically have problems with blood-brain barrier penetration due to high molecular weight, charge, or both. Exceptions include the polyene antibiotics, 28, 29 which have significant toxicity problems. Much attention has been given to the antimalarial drug quinacrine, which has anti-scrapie activity in cell culture, 30 crosses the blood-brain barrier, and is being administered to numerous CJD patients. However, there is no clear evidence that quinacrine is effective in vivo. We have found that the same is true of mefloquine (another anti-malarial drug), 31 curcumin (unpublished results), and a number of other CNS-permeable compounds that potently inhibit PrP Sc formation in cell culture. 32 In the absence of evidence of anti-TSE efficacy in vivo, it is hard to understand the rationale for continued clinical trials of quinacrine against CJD.
Delivery of Anti-TSE Compounds into the Brain
To bypass the blood-brain barrier, Doh-Ura and colleagues have used osmotic pumps to deliver PrP Sc inhibitors such as pentosan polysulfate directly to the brains of rodents via intraventricular cannulas. 33 As a result, significant extensions of scrapie incubation period were observed even with treatments directed against established CNS infections. Based on those results, similar intraventricular administrations of pentosan polysulfate have been initiated in human CJD patients, but the effects of such treatments are not clear.
cTPs, that is, porphyrins and phthalocyanines ( Figure  1 ), are among the most promising of the anti-TSE compounds. Compounds of this class are PrP-res inhibitors in cultured cells infected with sheep scrapie, mouse scrapie, and mule deer chronic wasting disease. 20, 21, 23 As noted above, cTPs can have strong prophylactic antiscrapie activity rivaling that of pentosan polysulfate. 24, 25 Although some porphyrins are thought to cross the blood-brain barrier to some extent, this may not be true of our cTPs that are the most effective when used prophylactically or in cell cultures.
To test the efficacy of these compounds against CNS infections, we have directly injected cTPs into the brain as a crude substitute for Doh-Ura's sophisticated intraventricular osmotic pumping technique. 34 When weekly injections of the anionic Fe(III)meso-tetra(4-sulfonatophenyl)porphine (Fe-TSP) were initiated 2 weeks after a high dose (10 6 lethal doses) intracerebral scrapie inoculation, the survival times increased by an average of 51%. Interestingly, indium-and zinc-bound TSP and various metal complexes of a cationic porphyrin meso-tetra(4-N,N,N-trimethylanilinium)porphine (TMP) had no statistically significant effects in the same experiment. In another experiment, porphyrins were mixed directly with the scrapie brain inoculum just prior to intracerebral injection to test for an ability to mask or decontaminate infectivity. Interestingly, Fe-TSP was less active in this protocol than Fe-TMP, which increased survival times as if the inoculum were diluted by 10 3 -10 4 .
Structure-Activity Relationships of cTPs
Compounds from each class of cTP in Figure 1 have shown anti-TSE activity in cell-free PrP conversion reactions, cell cultures, and animals. 20, 21, [23] [24] [25] 34 Many different types of structures were active, whereas others with seemingly similar structures were much less active. The results obtained thus far suggest that for anti-TSE activity, numerous permutations of cTP structure can often be tolerated, but their influence can depend on other structural elements and the type of anti-TSE assay employed. Such differences include peripheral ring substituents and centrally bound metals.
One property that appears to correlate with anti-TSE activity is the ability to assemble into supramolecular aggregates. Aggregation of many phthalocyanines and porphyrins to dimers, trimers, and higher-order oligomers in aqueous media is well-known. The extent of such selfaggregation is influenced by cTP structure and concentration, as well as the solution conditions. 35, 36 Certain cTPs can also occupy sites on proteins, nucleic acids, and other polymers as both monomers and π-stacked aggregates. 35, 37 In solution, aggregate formation could affect cTP tissue bioavailability, whereas assembly on the surface of a biopolymer such as PrP C or PrP Sc could block PrP conversion, propagation of infectivity, or both.
Comparison of anti-TSE activity with self-aggregation propensity for various metal PcS 4 's ( Figure 1 ) supports a relationship between the two properties. Specifically, the Al III derivatives exhibited much lower anti-TSE activities in vitro than did metal-free PcS 4 or several other metal PcS 4 's. 23 At the same time, the Al III derivative has a lower tendency to aggregate in aqueous media than the others. 36 Further studies are needed to test the role of supramolecular assembly in cTP anti-TSE activities. Fortunately, a variety of techniques can be used to monitor the nature of cTP interactions with themselves and with proteins. 35, 36 Furthermore, the use of cTPs in several other medical areas has provided useful information on the biodistribution, toxicity, retention, and methods of administration of cTPs. Particularly notable are the frequently low toxicities of cTPs. [37] [38] [39] 
Structure-Activity Relationships with Other Anti-TSE Compounds
Like the cTPs, several other types of inhibitors of PrP Sc accumulation that we have identified are planar, highly conjugated, multi-ringed molecules that are likely to have the ability to form π-stacked aggregates or similar interactions with planar nonionic surfaces on PrP molecules. Those with the best activity in vivo also tend to have one or more charged or polar moieties on the edges of the planar ring system. For example, the prototypic PrP Sc inhibitor Congo red [40] [41] [42] is a sulfonated dye (Figure 2 ) that is thought to form stacked aggregates within proteins such as RNA polymerase 43 and immunoglobulins 44 ( Figure 3C ).
Also notable are the observations that oligonucleotides, which contain polyanionic backbones and π-stacked bases, bind to PrP C and induce conformational changes. 11, 12, 45 More to the point are observations of PrP C binding, PrP Sc inhibition, and anti-TSE activity by phos-FIGURE 1. Representative cyclic tetrapyrrole (cTP) structures with anti-TSE activity. The cTPs most extensively studied have structures related to these. On the left, iron(III) deuteroporphyrin IX 2,4-bis(ethylene glycol), designated Fe III DPG 2 , represents one of many deuteroporphyrin IX derivatives with different substituents at the 2 and 4 ring positions (indicated by arrows). In the center, iron(III) meso-tetra(4-N-methylpyridyl)-porphine (Fe III TMPyP) represents synthetic porphyrins that possess aryl substituents (denoted by arrows) on the linking meso carbons but no peripheral ring substituents on pyrrole moieties. Aryl substituent variations include cationic 4-N,N,N-trimethylanilinium and anionic phenyl-4-sulfonates (not shown). On the right, phthalocyanines with one to four sulfonic acid peripheral substituents are represented by phthalocyanine tetrasulfonate (H 2 PcS 4 ). The structure shown does not designate specific binding sites for each sulfonate group in that the preparations we have used were mixtures of isomers. phorothioated oligonucleotides (PS-ONs). 26, 27 The importance of the extended oligomeric character of PS-ONs was indicated by the strong dependence of activity on polymer length. 27 PS-ON inhibition was also dependent upon the phosphorothioate modification of the oligonucleotide backbone, which adds hydrophobicity to the polymer, but was mostly independent of base composition. Even sulfated glycan inhibitors such as pentosan polysulfate, a polysaccharide containing ∼12-18 pentose disulfate sulfate units, and iota-carrageenan, a double helical sulfated glycosaminoglycan, 46 have structural analogies to both PSONs and stacked oligomers of sulfonated dyes and anionic cTPs, namely, repeated negative charges and hydrophobic domains (Figure 3) .
A Common Inhibitor Binding Site on PrP
These analogies raise the possibility that the anionic cTPs, sulfonated dyes, PS-ONs, and sulfated glycans exert their inhibition by binding to PrP molecules at the same or overlapping sites. Indeed, competitive binding studies have shown that sulfated glycans compete with Congo red 47 and PS-ONs 27 for binding to PrP C . It is tempting to speculate that the dimensions of this common inhibitor binding site on PrP C corresponds approximately to a PS-ON 25-mer because inhibitory activity is reduced substantially with shorter PS-ON polymers. 27 In that case, multiple cTPs, sulfonated dyes, and other planar aromatic molecules might stack together to mimick polymeric PSONs or sulfated glycans (Figure 4) . The display of multiple alternating anionic and nonpolar surfaces by such oligomeric inhibitors suggests that the binding site on PrP C should include repeated cognate cationic and nonpolar surfaces. Such surfaces might be provided by the five octapeptide repeats and additional pseudorepeats in the flexible amino-terminal domain. Each repeat contains a cationic histidine residue and an aromatic tryptophan (or tyrosine) residue. The histidines might pair with anionic substituents on the edges of the inhibitors, while the tryptophan side chains could interact with nonpolar surfaces and even intercalate between planar aromatic regions of inhibitor molecules (Figure 4) . Analyses of the sulfated glycan binding site on PrP C by several groups have produced evidence for the involvement of residues in three different segments of the amino acid sequence: the highly cationic amino-terminal residues, the octapeptide repeats, and a more carboxy-terminal site containing residues 110-128, with differing views as to which residues are most important. [48] [49] [50] We expect that the residues involved in binding different classes of anionic PrP Sc inhibitors might vary somewhat, depending on the size and specific nature of the particular inhibitor. For instance, long sulfated glycans or PS-ONs might be able to bind to residues in all three segments of PrP C , while the smaller planar aromatic inhibitors might have a preference for interacting with the tryptophan side chains of octapeptide repeats. In addition, planar aromatic inhibitors with anionic substituents might also be able to π-stack against themselves while forming ion pairs with adjacent PrP C molecules as depicted in the figure at the aminotermini of the PrP C molecules.
Whatever the precise PrP binding mechanism(s), one net effect of these inhibitors in several cases is the aggregation of PrP C in cells. For instance, it is known that pentosan polysulfate, 49 sulfonated dyes, 51 and the PSONs 27 cause PrP C to cluster on the surface of cells and then become internalized. Furthermore, we have found that Congo red and cTPs (R. Kodali and B. Caughey, unpublished data) can cause aggregation of recombinant PrP C . Hence, in the model depicted in Figure 4 , we show PrP C molecules being pulled together by the inhibitors. In each case, it seems plausible for these inhibitors to serve as a bridge between PrP C molecules. With this in mind, it is noteworthy that activity is eliminated by cutting Congo red in half 41 (see Figure 2) or removing a third ring system in some planar aromatic polyphenols. 19 Such molecules may lack sufficient planar aromatic area to be able to bind two PrP C molecules at once. Although for simplicity we show the dimerization of PrP C , the formation of higher order PrP C aggregates might well be induced in a similar fashion by the inhibitor molecules or their supramolecular aggregates. Alternatively, it remains possible that aggregation of PrP C is not mediated directly by the inhibitor molecules as depicted in the model but by induction of aggregation-prone conformations in PrP C . At the cellular level, the PrP C aggregation caused by these classes of inhibitors may lead to sequestration of PrP C in a state or subcellular location that is incompatible with conversion to PrP Sc .
Implications for Physiological Mechanisms of PrP Function and Conversion
The fact that several different structural classes of PrP Sc inhibitors share certain properties, PrP binding sites, and abilities to cause PrP aggregation and internalization begs the question of how these phenomena might relate to the normal function of PrP C and the mechanism of conversion to PrP Sc . More specifically, it seems likely that these inhibitors bind to a site normally reserved for physiological ligands that are important in the conversion to PrP Sc . Prime candidates for such ligands are sulfated glycosaminoglycans such as heparan sulfate, which bind to PrP C , 47, 52 associate with PrP Sc deposits in vivo, 53 and support PrP conversion. 8, 9 Consistent with this view is the observation that many of the PrP Sc inhibitors discussed above can be viewed as glycosaminoglycan analogues or mimics. If PrP molecules interact with polyanions, then it is also reasonable to expect that the polycationic inhibitors (e.g., branched polyamines 54 and cationic cTPs 23, 34 ) could mask cellular polyanionic molecules such as GAGs that must bind to induce and stabilize the conversion of PrP C . Polycations might also interact directly with PrP, possibly via bridging cations. In addition, crucial interactions with other cellular ligands and surfaces might be directly or indirectly affected by inhibitor binding. While such effects may block PrP Sc formation, they might also have negative consequences relating to functions of PrP C . Hopefully, further studies of the normal and disease-associated interactions and functions of PrP isoforms will suggest new and improved therapeutic strategies for the TSE diseases.
FIGURE 4.
Model of possible interactions between PrP C and various PrP Sc inhibitors that cause PrP C aggregation. The left panel shows diagrammatic PrP C structure emphasizing the planar aromatic tryptophan side chains in the octapeptide repeats and cationic residues in regions that have been implicated in sulfated glycan binding as described in the main text. In the middle panel, planar aromatic sulfonated inhibitors such as the sulfonated porphyrins, phthalocyanines, and azo dye molecules (e.g. Congo red) are shown to be stacked directly against one another while ion-pairing with cationic residues at the amino-terminus, and co-stacked with tryptophan (Trp) side chains in the octapeptide region while ion-pairing to histidine (His) residues. In the right panel, extended polyanionic inhibitors such as sulfated glycans and phosphorothioated oligonucleotides are also shown to bind via similar ion pairs and hydrophobic interactions with aromatic side chains in the octapeptide repeats. These interactions could result in dimerization (as shown) or higher order clustering of PrP C molecules as has been observed on the cell surface with several of these types of inhibitors. Transmissible spongiform encephalopathies (TSEs) 1 or prion diseases are associated with the misfolding of naturally occurring prion protein (PrP) into an abnormal isoform termed PrP Sc . Scrapie-infected murine neuroblastoma cells are commonly used to identify compounds with potential anti-TSE activity [1] because almost all compounds with in vivo anti-TSE activity also inhibit PrP Sc formation in these cells; however, many in vitro PrP Sc inhibitors have not delayed TSEs in vivo [2, 3] . Furthermore, cell-based assays are time consuming and costly which limits their utility for screening large numbers of compounds. Recently, antiprion screens using surface plasmon resonance [4] , fluorescence correlation spectroscopy [5] , and amyloid fibril formation [6] have been developed, which all show promise.
A novel in vitro antiprion screening method is presented here whose predictive ability to find anti-TSE compounds is validated by anti-TSE activity in rodent models. Phosphorothioate oligonucleotides (PS-ONs) bind strongly to natively folded recombinant PrP (rPrP) and are among the most potent anti-TSE compounds known [7] . PS-ONs longer than 30 bases are highly effective at preventing PrP Sc formation in cell culture and this activity is dependent on the sequence-independent amphipathic properties of phosphorothioate oligonucleotides [7] . Known antiprion compounds such as sulfated glycans bind at or near the PS-ON binding site on rPrP [7] , suggesting that both types of molecules reversibly bind to rPrP at the same binding site. Since this regiospecific and quantifiable binding was correlated to the anti-TSE activity of the competitor sulfated glycans, we reasoned that this competitive binding could be used as an indicator of in vivo anti-TSE activity. Thus, a fluorescence polarization (FP; reviewed in [8] )-based competitive binding assay was evaluated for its predictive accuracy with a larger set of compounds previously tested in rodents for anti-TSE activity [3, 6, [9] [10] [11] [12] .
Randomerl-FL 1 was synthesized with a single label using 3 0 -(6-fluorescein) CPG supports (Glen Research) and characterized as described [7] . Hamster rPrP (residues 23-231, the mature PrP sequence in vivo) was expressed in Escherichia coli without affinity tags and purified using a modification [13] of the method of Zahn et al. [14] . Desired concentrations of rPrP to be tested were diluted in FP assay buffer [7] in a black 96-well plate. The FP of Randomerl-FL was measured at excitation and emission wavelengths of 485/535 nM, respectively. Randomerl-FL was added to a final concentration of 3 or 10 nM and FP measured in a Tecan Ultra or Victor 3 microplate reader, respectively, with similar results. A saturating amount of rPrP (5 lg/mL; 200 nM) and Randomerl-FL at 3 or 10 nM were incubated together for at least 30 s to ensure complete binding [7] . Test compounds in dimethyl sulfoxide were freshly diluted in assay buffer and then immediately added to the Randomerl-FL/rPrP solution to a final concentration of 10 lM. Other plate formats were suitable for this assay and a number of samples measured over the course of several hours had essentially constant millipolarization merl-FL from rPrP by the test molecules was monitored as a reduction in FP in mP. Typical FP mP baseline values of solutions containing only Randomerl-FL were 59 ± 3. The rate of molecular tumbling decreases with binding events, thereby increasing the mP readout by increasing the polarization of light emitted from the excited fluorophore. An mP value of 261 ± 5 was typically obtained upon binding between rPrP and Randomerl-FL and the K D for this binding was 16 nM [7] . As expected, increasing concentrations of unlabeled Randomerl competed for binding to rPrP, which lowered mP values and indicated displacement of bound Randomerl-FL. Compounds in this assay were revalidated with a dose-response curve which was then used to generate K i values (50% competition of bound, Randomerl-FL). Each compound identified as a competitor was also further tested in the absence of rPrP to rule out direct interaction with free Randomerl-FL, which would be detected as an increase in FP readout. Table 1 lists 24 compounds previously determined to possess PrP Sc -inhibitory activity in infected cells and/or anti-TSE activity in rodents. A ''yes'' for cell culture antiscrapie activity indicates that the compound has an IC 50 (the concentration inhibiting 50% of PrP Sc formation in cells) value 610 lM in scrapie-infected murine neuroblastoma cells. A ''yes'' for in vivo antiscrapie activity means that the compound has at least demonstrated a statistically significant prophylactic effect in an animal model. Each compound was initially tested at 10 lM for the ability to displace rPrP from Randomerl-FL. Results from this screening were then compared to the cell-based PrP Sc inhibition by those compounds at 610 lM. By this simple and direct comparison the FP-based competition assay more accurately predicted the in vivo anti-TSE activity of these compounds than the cell-based PrP Sc inhibition assay (73% vs 40% accuracy, Table 1 ). Unfortunately, some compounds cannot be tested in scrapie-infected cells due to cytotoxicity, as seen with the tetracyclines included in Table 1 . Moreover, some PrP Sc inhibitors identified in cell culture failed to displace Randomerl-FL from rPrP in the FP-based assay, thus highlighting the need for complimentary in vitro models.
The relationship between K i (FP assay), cell culture IC 50 , and prophylactic anti-TSE activity in vivo was examined for 23 compounds previously tested for in vivo antiscrapie activity in rodents (Supplementary Table 1 ). Compounds with FP competition K i values of <6000 nM typically had anti-TSE activity in vivo (6 of 7), while 12 of the remaining 16 compounds with K i values P6000 nM did not. A trend between cell culture IC 50 values and in vivo anti-TSE prophylaxis is harder to define. Lower IC 50 values did not necessarily correlate with increased activity in vivo; however, virtually all of the compounds with in vivo activity also inhibited PrP Sc formation in scrapie-infected cell culture. The FP-based competition assay presented here measures the ability of test compounds to displace Randomer1-FL bound to rPrP. As Randomer1 strongly binds to rPrP and ranks among the most effective prophylactic anti-TSE compounds in vivo, this PrP binding site has direct relevance for anti-TSE activity in vivo [7] . Compounds identified by this method are likely to bind to the same site on rPrP as Randomerl. The FP competition assay is therefore an indirect way to screen libraries for compounds that bind to rPrP specifically at the Randomerl binding site. This distinguishes the FP-based competition assay from others measuring direct PrP-compound interactions, which may vary significantly in their specificity [4, 5] . The ability to quantify binding affinity specifically to a therapeutically relevant region of rPrP may explain the predictive capabilities of the FP assay and allow further detailed structure-activity relationship studies. On a practical level, the assay is well-suited to high-throughput screening because the FP reaction comes to equilibrium within 30 s, is stable for several hours at room temperature, and is readily adaptable to multiple plate formats.
Virtually every compound that has demonstrated in vivo anti-TSE activity also inhibits PrP Sc formation in infected neuroblastoma cells. However, these assays are labor intensive and require days for cell growth and PrP The transmissible spongiform encephalopathies (TSEs), or prion diseases, include Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy, chronic wasting disease of deer and elk, and scrapie of sheep and goats. The appearance of variant CJD, linked to consumption of bovine spongiform encephalopathy-infected cattle, has increased awareness of TSEs. These diseases are characterized by the accumulation of an abnormal protease-resistant form of prion protein (PrP-res), derived from normal prion protein (PrP-sen) (2). Considerable evidence indicates that PrP-res is either the infectious TSE agent or a critical component (8) .
Some compounds have been able to delay scrapie onset in rodents when administered at or near the time of peripheral infection, but few have helped after intracerebral (i.c.) inoculation. Two compounds effective after i.c. scrapie inoculation include pentosan polysulfate (PPS) (5) and Fe(III)mesotetra(4-sulfonatophenyl)porphine (FeTSP) (7), which, due to poor blood-brain barrier penetration, must be administered directly to the brain. PPS, a semisynthetic carbohydrate polymer approved as an oral therapy for interstitial cystitis (Elmiron), is being infused into the brains of CJD patients as an experimental therapy (11) . FeTSP, a porphyrin, recently demonstrated antiscrapie activity when administered via i.c. injections to mice with established brain infections (7) . Here, we report significant antiscrapie activity by using the combined formulation of PPS and FeTSP.
Increased survival time after scrapie inoculation is a common measure of antiscrapie activity. Here, transgenic mice overexpressing hamster prion protein (Tg7) were used because of their relatively short scrapie incubation period (9). All mice were inoculated i.c. with 50 l of 1% (wt/vol) brain homogenate from 263K scrapie-infected hamster brains. The first of five weekly i.c. drug injections was initiated 14, 28, or 35 days later. Tg7 mice in this study were euthanized when they showed obvious scrapie clinical symptoms, which in this strain is usually within 1 day of death (5) . Animal procedures were approved by the guidelines of the Rocky Mountain Laboratory Animal Care and Use Committee. FeTSP and Fe(III)mesotetra(4-N,N,N-trimethylanilinium)porphine (FeTAP) were purchased from Porphyrin Products (Logan, UT), and PPS was a gift from Biopharm Australia (Bondi Beach, Australia). Statistical calculations were made using GraphPad Prism 4 software.
Scrapie-infected mice injected i.c. separately with either PPS or FeTSP beginning 14 days after inoculation had an average increased survival time of 26.5 or 16.9 days, respectively (Fig.  1A) . Treatment with a combination of PPS and FeTSP by the same dosing regimen increased survival time by an average of 52.4 days (Fig. 1A) . This delay was 9 days or 21% more than the sum of the delays induced by the drugs individually (26.5 days ϩ 16.9 days ϭ 43.4 days). Using two-way analysis of variance (ANOVA) (10), the combined use of PPS and FeTSP produced a statistically significant positive interaction effect (P ϭ 0.0004). In contrast to combined FeTSP and PPS treatment, FeTAP, an iron-substituted porphyrin without antiscrapie activity under these circumstances, did not result in an increased antiscrapie effect when combined with PPS (Fig. 1B) . Consequently, although FeTSP and PPS treatment resulted in an enhanced antiscrapie effect, this is not a characteristic of all porphyrins.
Testing of PPS, FeTSP, and their combination was also started at 28 or 35 days after inoculation or at the onset of clinical symptoms (ϳ40 to 50 days). Treatment starting at 28 days postinoculation was less effective than at 14 days. FeTSP increased survival time by an average of 3.4 days, marginally significant by an unpaired t test (P ϭ 0.057), but PPS treatment extended life span by an average of 12.4 days (Fig. 2A) . The combination extended life span by an average of 29.0 days, which is 13.2 days or 84% more than the sum of the singlecompound treatment extensions. As with treatment starting at 14 days, two-way ANOVA showed a statistically significant positive interactive effect for the combined use of PPS and FeTSP (P ϭ 0.03). Treatment starting at 35 days postinoculation demonstrated no significant benefit with either singletreatment group or the combination (Fig. 2B) . To investigate PPS and FeTSP as a possible therapy for late-stage treatment, animals were treated with one dose of PPS and FeTSP intracerebrally and 10 mg PPS/kg of body weight intraperitoneally at the onset of clinical symptoms. Even with the additional intraperitoneal dose of PPS, no benefit was observed.
Determination of the antiscrapie mechanism of the FeTSPand-PPS combination treatment in vivo is hindered by an incomplete understanding of TSE infection and disease mechanisms. However, two-way ANOVA of the results from combination treatment at 14 and 28 days postinoculation suggests synergy rather than a simple additive effect (10) . One possible explanation is that the presence of PPS or FeTSP might increase the half-life of the other compound by inhibiting an enzyme important in that compound's metabolism. Alternatively, each may differentially bind PrP and/or other molecules which might slow PrP-res accumulation or its pathological consequences. PPS and FeTSP individually inhibit the formation of PrP-res in chronically scrapie-infected cell cultures (3, 4) ; however, combinations of PPS and FeTSP were additive, and not synergistic, in this in vitro PrP-res inhibition model (Fig. 3) . Also, PPS treatment alone has been shown to vastly reduce PrP-res in scrapie-infected mouse brains (5) . This suggests that the in vivo effects seen may involve more-complex biological interactions than the inhibition of PrP-res accumulation seen in cell culture or in vivo.
Regardless of the mechanism of action, on a practical level, the combination therapy was more effective than separate treatments. As PPS is being infused into the brains of CJD patients, the initial results reported here suggest that the addition of FeTSP to the treatment might be beneficial. Because the results from weekly i.c. dosing were so encouraging, further experiments are planned to continuously deliver PPS, FeTSP, and PPS/FeTSP to the brain by an infusion pump. It is hoped that brain infusion will be a more effective route of administration by providing a more constant concentration of drug over a longer period of time and that it will also allow a greater total dose of the combination to be safely administered. Finally, toxicology studies of PPS/FeTSP are needed, but a number of other porphyrins and porphyrin analogs have been approved for clinical use (1) . Based on this finding, combination therapy for TSE treatment may lead to more-effective intervention for neurodegenerative diseases in general. 
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